In This Issue
In the Spotlight
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections
Triple-vaccinated myeloma patients lack CD8 responses and display suboptimal antibody responses, particularly against newer SARS-CoV-2 variants. Live-virus neutralization activity, rather than antibody titers, correlate with breakthrough infections.
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
A Phase I trial of early-line anti-BCMA and anti-CD19 CAR T cells in high-risk multiple myeloma patients demonstrated safety and feasibility of dual-target CAR T therapy with maintenance as an early-line treatment.
Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis
Comprehensive genomics reveal high prevalence of low hypodiploidy in older patients with B-ALL and track its origin to TP53-deficient age-associated clonal hematopoiesis.
In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
A multiplex-edited mouse model of Richter syndrome transformation from CLL reveals dysregulated signaling pathways and potential therapeutic targets.